CAR-T cells for multiple sclerosis
Immunotherapy to prevent inflammation has been successful in early stages for some diseases, but had no effect at later stages.
The researchers carried out first individual treatment with a fully human CD19 CAR-T cell therapy (KYV-101) in two patients with progressive MS. CD19 CAR-T cell therapy showed tolerable short-term safety in two patients with MS.
The authors also observed CAR-T cell expansion in cerebrospinal fluid without neurotoxicity and intrathecal antibody production decreased after CAR-T cell infusion in one patient indicating positive effect on inflammation by the therapy.
Larger clinical studies with more patients would be required to assess CD19 CAR-T cells in MS patients.
